Unknown

Dataset Information

0

Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.


ABSTRACT: Mucopolysaccharidoses (MPSs) constitute a heterogeneous group of lysosomal storage disorders characterized by the lysosomal accumulation of glycosaminoglycans (GAGs). Although lysosomal dysfunction is mainly affected, several cellular organelles such as mitochondria, endoplasmic reticulum, Golgi apparatus, and their related process are also impaired, leading to the activation of pathophysiological cascades. While supplying missing enzymes is the mainstream for the treatment of MPS, including enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), or gene therapy (GT), the use of modulators available to restore affected organelles for recovering cell homeostasis may be a simultaneous approach. This review summarizes the current knowledge about the cellular consequences of the lysosomal GAGs accumulation and discusses the use of potential modulators that can reestablish normal cell function beyond ERT-, HSCT-, or GT-based alternatives.

SUBMITTER: Leal AF 

PROVIDER: S-EPMC9820209 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.

Leal Andrés Felipe AF   Benincore-Flórez Eliana E   Rintz Estera E   Herreño-Pachón Angélica María AM   Celik Betul B   Ago Yasuhiko Y   Alméciga-Díaz Carlos Javier CJ   Tomatsu Shunji S  

International journal of molecular sciences 20221228 1


Mucopolysaccharidoses (MPSs) constitute a heterogeneous group of lysosomal storage disorders characterized by the lysosomal accumulation of glycosaminoglycans (GAGs). Although lysosomal dysfunction is mainly affected, several cellular organelles such as mitochondria, endoplasmic reticulum, Golgi apparatus, and their related process are also impaired, leading to the activation of pathophysiological cascades. While supplying missing enzymes is the mainstream for the treatment of MPS, including enz  ...[more]

Similar Datasets

| S-EPMC8468223 | biostudies-literature
| S-EPMC5203965 | biostudies-literature
| 2131952 | ecrin-mdr-crc
| S-EPMC10046358 | biostudies-literature
2021-06-04 | PXD026524 |
| S-EPMC8001210 | biostudies-literature
| S-EPMC6639430 | biostudies-literature
| S-EPMC7479174 | biostudies-literature
| S-EPMC9597211 | biostudies-literature
| S-EPMC8182300 | biostudies-literature